USAoderna announced today that their COVID-19 vaccine produces “robust” levels of antibodies for children aged six months to six years that are similar to created by vaccinated adults with the blow.
The results are part of the company’s KidCOVE study and will be submitted to the Food and Drug Administration (FDA) for emergency use authorization for the youngest and eventual group of children eligible for COVID vaccination. -19, Moderna said in a statement.
In the study, nearly 7,000 children aged six months to six years were randomly assigned to receive two doses of Moderna’s mRNA-based COVID-19 vaccine, or two doses of a placebo. The dosage for this age group is a quarter Now approved for adults. Children vaccinated with this vaccine produced antibodies against SARS-CoV-2 at levels similar to those produced by adults after higher doses of the vaccine, potentially reflecting the system. the child’s immune system works more effectively. Those antibodies resulted in 43.7% effectiveness in protecting children aged six months to two years from infection Omicron variant of the COVID-19 virus, and 37.5% in people aged two to six years. None of the infected children in the study were hospitalized or died.
Currently, Moderna’s vaccine is only approved for people over the age of 18, while Pfizer-BioNTech’s is approved for adults and holds an emergency use permit for adults. people between five and 18 years old. But these results could put Moderna ahead of Pfizer-BioNTech in getting authorization to distribute its vaccines to younger children. In addition to seeking approval for the vaccine in children six months to six years of age, Moderna is also asking the FDA to authorize two doses of the mRNA vaccine for children six to 12 years of age, based on data provided to the agency. administer safe and effective injections in that age group.
While Pfizer-BioNTech has sent a request in February to obtain FDA approval of the vaccine for the youngest age group, the companies and agencies decided to delay the review of the application until April, when more data on children receiving doses of the vaccine will be available. third complement of the vaccine. The two-dose regimen has not proven effective in protecting the youngest children from infection and disease, especially against the Omicron variant, as health officials had hoped.
Children under the age of six are the last group to receive the COVID-19 vaccine, and making sure their shots are safe and effective is important because new Omicron sub-variable, BA.2continues to cause many new infections and virus control measures such as wearing a mask are being abandoned in schools and other public places across the United States
Other must-read stories from TIME